![EISAI ANNOUNCES COMMENCEMENT OF OPERATIONS OF A NEW RESEARCH FACILITY AT H3 BIOMEDICINE INC., A U.S. RESEARCH SUBSIDIARY TO FACILITATE CUTTING-EDGE CANCER GENOMICS-DRIVEN DRUG DEVELOPMENT | News Release:2011 | Eisai Co., Ltd. EISAI ANNOUNCES COMMENCEMENT OF OPERATIONS OF A NEW RESEARCH FACILITY AT H3 BIOMEDICINE INC., A U.S. RESEARCH SUBSIDIARY TO FACILITATE CUTTING-EDGE CANCER GENOMICS-DRIVEN DRUG DEVELOPMENT | News Release:2011 | Eisai Co., Ltd.](https://www.eisai.com/news/images/enews201177-1.jpg)
EISAI ANNOUNCES COMMENCEMENT OF OPERATIONS OF A NEW RESEARCH FACILITY AT H3 BIOMEDICINE INC., A U.S. RESEARCH SUBSIDIARY TO FACILITATE CUTTING-EDGE CANCER GENOMICS-DRIVEN DRUG DEVELOPMENT | News Release:2011 | Eisai Co., Ltd.
![Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium](https://mma.prnewswire.com/media/1397131/MM87168LOGO.jpg?p=facebook)
Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium
![Eisai co-establishes “Global Health Innovative Technology Fund,” Japan's first public–private partnership to eliminate infectious disease in developing countries | Infectious Diseases Research & Development | Eisai Co., Ltd. Eisai co-establishes “Global Health Innovative Technology Fund,” Japan's first public–private partnership to eliminate infectious disease in developing countries | Infectious Diseases Research & Development | Eisai Co., Ltd.](https://www.eisai.com/sustainability/atm/innovation/images/008_img_01.jpg)